Common antibiotic may help treat patients with difficult asthmaDecember 18th, 2007 - 3:13 pm ICT by admin
Washington, Dec 18 (ANI): A collaborative study has shown that a commonly available antibiotic, macrolide, can improve the quality of life of patients with difficult asthma, and may also generate significant health care savings.
The study, conducted by researchers from the University of Newcastle and Hunter New England Health in collaboration with the Hunter Medical Research Institute (HMRI) Viruses, Infections/Immunity,Vaccines and Asthma (VIVA) Research Program, has indicated that macrolide antibiotics could prove a successful therapy in conjunction with current asthma treatment.
Present asthma medication is focused on treating a particular cell, called an eosinophil. Increased levels of eosinophils are thought to be responsible for inflammation of the airways. However, almost half of people with asthma symptoms have normal levels of eosinophils.
In a previous study we have shown that an inflammatory cell called the neutrophil is increased in some asthma patients and that treatments are needed to combat other types of inflammation in people with asthma, Dr Jodie Simpson from the University of Newcastles Priority Research Centre for Asthma and Respiratory Diseases said.
For the study, researchers examined 45 people who had poor asthma control and were taking high daily maintenance doses of inhaled corticosteroids. In addition to their regular asthma therapy, participants received a macrolide antibiotic (called klacid) or placebo medication for eight weeks.
In this study we have shown that treatment with a macrolide antibiotic for eight weeks significantly reduced inflammation in the airways and improved quality of life in patients with difficult asthma, Dr Simpson said..
Patients with non-eosinophilic asthma particularly benefited from this treatment and this group of patients had the biggest response to the treatment. This treatment significantly reduced the number of neutrophils in the airway.
This finding is significant because 5 to 10 per cent of asthma cases are considered difficult and these account for 50 per cent of asthma treatment and health care costs, Dr Simpson added.
The study is published in the American Journal of Respiratory and Critical Care Medicine. (ANI)
- Biggest ever asthma study set to start Down Under - Oct 17, 2008
- New therapeutic target for asthma, other lung disorders identified - Apr 18, 2011
- Asthma patients should stay away from high-fat meals - May 17, 2010
- Indian-origin scientist suggests use of CT scans for severe asthma - Jun 15, 2010
- Four novel biomarkers that may help diagnose asthma, COPD identified - Mar 12, 2011
- Asthma linked to bacterial communities in the airway - Feb 18, 2011
- Potential cancer drug being tested for asthma treatment - Dec 10, 2009
- Common antibiotics, BP medications a bad mix: Study - Jan 18, 2011
- Internet monitoring strategy effective for severe asthma patients - May 17, 2010
- Asthma patients may benefit from antibody injections - Mar 05, 2009
- Novel drug may benefit cystic fibrosis patients - Dec 18, 2010
- Now, alternate therapy for adults with poorly controlled asthma - Sep 20, 2010
- Key mechanism of childhood respiratory disease identified - Mar 08, 2011
- Bacteria linked to asthma attacks in children - Oct 08, 2010
- Imbalanced diet, inadequate exercise may cause asthma in kids - Sep 17, 2010
Tags: asthma medication, asthma patients, asthma symptoms, asthma therapy, asthma treatment, difficult asthma, health care savings, hmri, inflammatory cell, inhaled corticosteroids, jodie simpson, macrolide antibiotic, macrolide antibiotics, maintenance doses, medical research institute, poor asthma control, priority research, respiratory diseases, types of inflammation, university of newcastle